Furthermore, in moderna and AstraZeneca Phase 2a human clinical trials in Finland (AZD8601), patients with ischemic heart disease receive VEGFA modRNA delivered naked in citrate‐sucrose buffer.[49] The mechanism of action that allows naked modRNA to enter the cell, as both modRNA and the cell membrane are negatively charged, is not yet clear. Here, VEGFA is linked to coronary artery disorder.